BioFinlandin jäsen

Askel Healthcare is a Finnish medical technology company set to transform surgical knee cartilage treatment and recovery. The number of people suffering from painful knee osteoarthritis worldwide has more than doubled over the past three decades, with the main cause being untreated cartilage damage. Our mission is to keep people in motion through our universal COPLA® implant, which is a ground-breaking innovation for the repair of knee cartilage defects. It is easy to implant and enables a fast recovery to pain-free activity. The implant is the result of more than 10 years of orthopedic and tissue engineering research at the University of Helsinki and Tampere University in Finland. Our founders’ extensive backgrounds in orthopedic research, our high-caliber global collaboration network, and our competent employees make us a global frontrunner in cartilage repair. The company is currently in the clinical phase. The company’s short-term strategic focus is on obtaining EU and US market authorizations by strengthening the clinical evidence of the COPLA® implant. The main goal is market launch and commercialization in EU and the US by 2028.